arrow
R

Raffaella Greco

IRCCS San Raffaele Hospital
H指数:53
被引数:9,832

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

The role of palliative and supportive care in haematopoietic cell transplantation and cellular therapy. Recommendations from the EBMT practice harmonisation and guidelines committee

姑息治疗和支持性护理在造血细胞移植和细胞治疗中的作用。EBMT实践协调与指南委员会的建议

2026-10-260
OAAI
Publisher Correction: defining global priorities in hematopoietic transplantation and cellular therapy: a statement paper from the EBMT global committee

出版商更正:定义造血移植和细胞治疗领域的全球优先事项:EBMT全球委员会的一份声明文件

2026-10-120
OAAI
Empirical Therapy in High-Risk Hematological Patients with Carbapenem-Resistant Enterobacterales Colonization: Real-World Treatment Decisions and Antimicrobial Stewardship Implications

在高风险血液病患者中,对碳青霉烯耐药肠杆菌科细菌定植的的经验性治疗:真实世界治疗决策和抗菌药物合理使用的影响

2026-10-080
OA
Correction: Secondary autoimmune and inflammatory diseases after allogeneic hematopoietic stem cell transplantation: a retrospective study from the EBMT transplant complications and autoimmune diseases working parties

更正:异基因造血干细胞移植后的继发性自身免疫性和炎症性疾病:来自EBMT移植并发症和自身免疫性疾病工作组的事后研究

2026-09-250
PRE
Defining global priorities in hematopoietic transplantation and cellular therapy: a statement paper from EBMT Global ComMittee

定义全球造血移植和细胞治疗的优先事项:EBMT全球委员会声明文件

2026-08-110
OAAI
Late complications after autologous HSCT for autoimmune diseases: a retrospective survey from the autoimmune diseases working party (ADWP), transplant complications working party (TCWP) and paediatric diseases working party (PDWP) of the european society for blood and marrow transplantation (EBMT)

自体造血干细胞移植治疗自身免疫性疾病的晚期并发症:欧洲血液与骨髓移植学会(EBMT)自身免疫性疾病工作组(ADWP)、移植并发症工作组(TCWP)和儿科疾病工作组(PDWP)的回顾性调查

2026-07-270
PRE
Secondary autoimmune and inflammatory diseases after allogeneic hematopoietic stem cell transplantation: a retrospective study from the EBMT transplant complications and autoimmune diseases working parties

异基因造血干细胞移植后的继发性自身免疫性和炎症性疾病:来自EBMT移植并发症和自身免疫性疾病工作组的事后研究

2026-07-270
PRE
The 2024 EBMT activity report: crossing one million HCTs and 20,000 CAR-T. A landmark in cellular therapy

2024年EBMT活动报告:完成一百万例HCT和2万例CAR-T。细胞疗法的重要里程碑

2026-05-270
OAAI
Impact of donor and recipient EBV serostatus on transplant outcomes in patients with acute leukemia after haploidentical hematopoietic cell transplantation with post-transplant cyclophosphamide: Infectious Diseases Working Party EBMT retrospective study

供体和受者EBV血清状态对异基因造血细胞移植后环磷酰胺治疗的急性白血病患者移植结局的影响:EBMT感染性疾病工作组回顾性研究

2026-05-040
PRE
Treosulfan/fludarabine versus thiotepa/busulfan/fludarabine for allogeneic haematopoietic cell transplantation in lymphoma in the post-transplant cyclophosphamide era: A GETH-TC study

曲奥舒泛/氟达拉滨与替尼泊苷/白消安/氟达拉滨在移植后环磷酰胺时代的淋巴瘤异基因造血细胞移植中的比较:一项GETH-TC研究

2026-02-120
PRE
Impact of busulfan- versus treosulfan-based conditioning on the incidence of sinusoidal obstruction syndrome/veno-occlusive disease after allogeneic hematopoietic cell transplantation: a dual-center real-world study

基于马利兰与奥莫福安的预处理方案对异基因造血细胞移植后肝窦阻塞综合征/静脉闭塞病发生率的影响:一项双中心真实世界研究

2025-11-180
PRE
BEAM/ATG or cyclophosphamide/ATG as conditioning regimen in autologous haemopoietic stem cell transplantation for multiple sclerosis: a retrospective analysis of the EBMT autoimmune diseases working party

BEAM/ATG 或环磷酰胺/ATG 作为自体造血干细胞移植治疗多发性硬化中的预处理方案:EBMT 自身免疫性疾病工作组的一项回顾性分析

2025-09-290
OAAI
Indications for haematopoietic cell transplantation and CAR-T for haematological diseases, solid tumours and immune disorders: 2025 EBMT practice recommendations

造血细胞移植和CAR-T在血液病、实体瘤和免疫紊乱中的适应证:2025年EBMT实践建议

2025-09-090
OAAI
Autologous haematopoietic stem cell transplantation for rheumatic diseases: best practice recommendations from the EBMT Practice Harmonization and Guidelines Committee

自体造血干细胞移植治疗风湿性疾病:EBMT实践协调与指南委员会的最佳实践建议

2025-08-200
OAAI
Biomarkers for an early diagnosis of immune effector cell associated-hemophagocytic syndrome

免疫效应细胞相关噬血细胞综合征的早期诊断生物标志物

2025-08-140
PRE